Next Article in Journal
Reversing Type 2 Diabetes: The Time for Lifestyle Medicine Has Come!
Previous Article in Journal
The Effectiveness of Probiotics in the Treatment of Inflammatory Bowel Disease (IBD)—A Critical Review
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Comment

Comments to the Editor Re: Papukashvili et al. Nutrients 2020, 12, 184

EuSci LLC, 1309 S 204th St, #293, Elkhorn, NE 68022, USA
Nutrients 2020, 12(7), 1965; https://doi.org/10.3390/nu12071965
Submission received: 19 January 2020 / Accepted: 24 April 2020 / Published: 2 July 2020
(This article belongs to the Section Nutrition and Metabolism)
Papukashvili et al. [1] recently covered the enzyme semicarbazide-sensitive amine oxidase (SSAO) as a potential molecular target for the management of obesity and related diseases. While the paper is interesting, there are aspects which require clarification as it relates to caffeine.
First, the authors explain in the text of the paper that caffeine demonstrated an inhibitory concentration (IC) of 0.1–10 mM with an IC50 of 0.8 ± 0.3 mM (Table I incorrectly uses nM for the unit of measurement) for SSAO (from bovine serum) activity, which they claim roughly corresponds to 1–4 cups of regular coffee and is consistent with a daily dose of 400 mg of caffeine. However, this is not correct. The IC50 for caffeine of 0.8 mM (millimolar) is well beyond the peak plasma concentration (Cmax) that humans experience after 1–4 cups of coffee or 400 mg of caffeine [2]. For example, a 100 mg oral dose of caffeine administered as coffee produced a Cmax of approximately 2.5 mg/L, while 0.8 mM is equivalent to approximately 155 mg/L, which is nearly twice the known lethal concentration of 80 mg/L for humans [2]. Fredholm [3] noted long ago that because plasma caffeine concentrations experienced after humans ingest caffeine-containing beverages are typically below 100 µmol (0.1 mM) or around 19.4 mg/L, mechanisms explaining caffeine’s therapeutic effects should be sought in this range, while those requiring concentrations in the mM range are only of potential toxicological interest. Thus, like many potential targets of caffeine, SSAO does not appear to be relevant at non-toxic or non-lethal concentrations [2], an important distinction in order to avoid consumers being misled about the potential weight loss effects of caffeine based upon in vitro data [4].
Second, the authors indicate that caffeine is an effective agent for causing weight loss. However, the work cited, such as that by Westerterp-Plantenga et al. [5], did not provide caffeine as an intervention but rather a green tea extract to individuals who were habitual consumers of either high or low amounts of caffeine. Since the source of these subjects’ caffeine was mainly coffee, it would seem premature to conclude that caffeine alone was responsible. While caffeine itself is well known to increase lipolysis and thermogenesis, only a limited amount of the liberated fatty acids are oxidized in a resting state, leading to very limited, if any, effects upon fat mass or body weight [6,7,8]. There is some evidence that coffee or coffee extracts may produce small to modest weight and/or fat loss in humans but this would be unlikely to suffice as an actual treatment for obesity and importantly, these effects are unlikely to be due to caffeine alone [9,10].

Funding

This research received no external funding.

Conflicts of Interest

The author has previously served as a consultant to companies in the dietary supplement industry who have manufactured products containing caffeine.

References

  1. Papukashvili, D.; Rcheulishvili, N.; Deng, Y. Attenuation of Weight Gain and Prevention of Associated Pathologies by Inhibiting SSAO. Nutrients 2020, 12, 184. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Willson, C. The clinical toxicology of caffeine: A review and case study. Toxicol. Rep. 2018, 5, 1140–1152. [Google Scholar] [CrossRef] [PubMed]
  3. Fredholm, B. On the mechanism of action of theophylline and caffeine. Acta. Med. Scand. 1985, 217, 149–153. [Google Scholar] [CrossRef] [PubMed]
  4. Willson, C.M.; Grundmann, O. In vitro assays in natural products research—A matter of concentration and relevance to in vivo administration using resveratrol, α-mangostin/γ-mangostin and xanthohumol as examples. Nat. Prod. Res. 2017, 31, 492–506. [Google Scholar] [CrossRef] [PubMed]
  5. Westerterp-Plantenga, M.S.; Lejeune, M.P.G.M.; Kovacs, E.M.R. Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation. Obes. Res. 2005, 13, 1195–1204. [Google Scholar] [CrossRef] [PubMed]
  6. Acheson, K.J.; Gremaud, G.; Meirim, I.; Montigon, F.; Krebs, Y.; Fay, L.B.; Gay, L.J.; Schneiter, P.; Schindler, C.; Tappy, L. Metabolic effects of caffeine in humans: Lipid oxidation or futile cycling? Am. J. Clin. Nutr. 2004, 79, 40–46. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. European Food Safety Authority (EFSA). Scientific opinion on the substantiation of health claims related to caffeine and increased fat oxidation leading to a reduction in body fat mass (ID 735, 1484), increased energy expenditure leading to a reduction in body weight (ID 1487), increased alertness (ID 736, 1101, 1187, 1485, 1491, 2063, 2103) and increased attention (ID 736, 1485, 1491, 2375) pursuant to article 13(1) of regulation (EC) No. 1924/2006. EFSA J. 2011, 9, 2054. [Google Scholar]
  8. Astrup, A.; Breum, L.; Toubro, S.; Hein, P.; Quaade, F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double-blind trial. Int. J. Obes. Relat. Metab. Disord. 1992, 16, 269–277. [Google Scholar] [PubMed]
  9. Muhammad, H.F.L.; Sulistyoningrum, D.C.; Huriyati, E.; Lee, Y.Y.; Manan Wan Muda, W.A. The interaction between coffee:caffeine consumption, UCP2 gene variation, and adiposity in adults-a cross-sectional study. J. Nutr. Metab. 2019, 2019, 9606054. [Google Scholar] [CrossRef] [PubMed]
  10. Farias-Pereira, R.; Park, C.S.; Park, Y. Mechanisms of action of coffee bioactive components on lipid metabolism. Food Sci. Biotechnol. 2019, 28, 1287–1296. [Google Scholar] [CrossRef] [PubMed]

Share and Cite

MDPI and ACS Style

Willson, C. Comments to the Editor Re: Papukashvili et al. Nutrients 2020, 12, 184. Nutrients 2020, 12, 1965. https://doi.org/10.3390/nu12071965

AMA Style

Willson C. Comments to the Editor Re: Papukashvili et al. Nutrients 2020, 12, 184. Nutrients. 2020; 12(7):1965. https://doi.org/10.3390/nu12071965

Chicago/Turabian Style

Willson, Cyril. 2020. "Comments to the Editor Re: Papukashvili et al. Nutrients 2020, 12, 184" Nutrients 12, no. 7: 1965. https://doi.org/10.3390/nu12071965

APA Style

Willson, C. (2020). Comments to the Editor Re: Papukashvili et al. Nutrients 2020, 12, 184. Nutrients, 12(7), 1965. https://doi.org/10.3390/nu12071965

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop